The cardiac glycoside ouabain activates NLRP3 inflammasomes and promotes cardiac inflammation and dysfunction.
Cardiac glycosides such as digoxin are Na+/K+-ATPase inhibitors that are widely used for the treatment of chronic heart failure and cardiac arrhythmias; however, recent epidemiological studies have suggested a relationship between digoxin treatment and increased mortality. We previously showed that...
Main Authors: | Motoi Kobayashi, Fumitake Usui-Kawanishi, Tadayoshi Karasawa, Hiroaki Kimura, Sachiko Watanabe, Nathan Mise, Fujio Kayama, Tadashi Kasahara, Naoyuki Hasebe, Masafumi Takahashi |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5426608?pdf=render |
Similar Items
-
The crystal-induced activation of NLRP3 inflammasomes in atherosclerosis
by: Tadayoshi Karasawa, et al.
Published: (2017-09-01) -
Role of the NLRP3 Inflammasome in Preeclampsia
by: Koumei Shirasuna, et al.
Published: (2020-02-01) -
Cardiac Glycoside Ouabain Exerts Anticancer Activity via Downregulation of STAT3
by: Jie Du, et al.
Published: (2021-06-01) -
Cryo-sensitive aggregation triggers NLRP3 inflammasome assembly in cryopyrin-associated periodic syndrome
by: Tadayoshi Karasawa, et al.
Published: (2022-05-01) -
Cardiac glycoside ouabain efficiently targets leukemic stem cell apoptotic machinery independent of cell differentiation status
by: Jirarat Poohadsuan, et al.
Published: (2023-10-01)